Sorrento Therapeutics to Present at Two Healthcare Conferences
SAN DIEGO, Sept. 6, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today that Dr. Henry Ji, President and CEO, will present a corporate overview at two upcoming conferences.
Rodman & Renshaw Annual Global Investment Conference
Sorrento is scheduled to present at the Annual Rodman & Renshaw Global Investment Conference at the Millennium Broadway Hotel in New York, NY on Tuesday, September 10, 2013 at 4:55 PM ET (Room 7.03). Dr. Ji will be available for one-on-one meetings during the conference.
Stifel Healthcare Conference 2013
Sorrento is scheduled to present at the Stifel Healthcare Conference at the Four Seasons Hotel in Boston, MA on Thursday, September 12, 2013 at 4:25 PM ET (Blaxton Room). Dr. Ji will be available for one-on-one meetings during the conference.
The presentation will be webcast live at http://www.veracast.com/stifel/healthcare2013/main/player.cfm?eventName=2145_sorren and can also be accessed through the investor relations page at www.sorrentotherapeutics.com. A replay of the presentation will be available at www.sorrentotherapeutics.com and will be archived for 90 days.
About Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs in the Unites States, Europe and additional international markets. Sorrento Therapeutics' primary therapeutic focus is oncology but it is also developing therapeutics products for other indications, including inflammation, metabolic, and infectious diseases. Sorrento Therapeutics' proprietary G-MAB® fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutic product candidates that bind to disease targets appropriate for antibody therapy. Sorrento Therapeutics is also developing proprietary antibody drug conjugates (ADCs) as well as antibody formulated drug conjugates (AfDC) combining its G-MAB® antibodies and anti-tumor agents. On March 7, 2013, we entered into an exclusive option agreement with IgDraSol, Inc., a private company focused on developing oncologic agents for the treatment of metastatic breast cancer, or MBC, non-small cell lung cancer, or NSCLC, and other cancers.
More information is available at www.sorrentotherapeutics.com
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Words such as "assumes," "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. Forward-looking statements include statements about the preclinical and clinical development of Sorrento's human antibody therapeutics. All such forward-looking statements are based on Sorrento's current beliefs and expectations, and should not be regarded as a representation by Sorrento that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Sorrento's businesses; the scope and validity of patent protection for Sorrento's platform technologies, and the risk that the development or commercialization of product candidates may infringe the intellectual property rights of others; the potential that Sorrento may require substantial additional funding in order to obtain regulatory approval for and commercialize Sorrento Therapeutics' proprietary G-MAB® fully-human antibody library platform technologies or product candidates; and additional risks set forth in Sorrento Therapeutics' filings with the Securities and Exchange Commission. These forward-looking statements represent Sorrento Therapeutics' judgment as of the date of this release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and STI undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
SOURCE Sorrento Therapeutics, Inc.